Audrey Nosbaum
Overview
Explore the profile of Audrey Nosbaum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
1449
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ezzedine K, Hourblin V, Connetable S, Ruiz F, Ziad A, Sobczak A, et al.
J Eur Acad Dermatol Venereol
. 2025 Feb;
PMID: 39981849
No abstract available.
2.
Guironnet-Paquet A, Hamzeh-Cognasse H, Berard F, Cognasse F, Richard J, Yonis H, et al.
Front Immunol
. 2025 Feb;
15:1492672.
PMID: 39896810
Background: Immunological disturbances (anti-type I IFN auto-antibody production, cytokine storm, lymphopenia, T-cell hyperactivation and exhaustion) are responsible for disease exacerbation during severe COVID-19 infections. Methods: In this study, we set...
3.
Beyrouti A, Deuze J, Fontas E, Foureau A, Barbarot S, Aubert H, et al.
J Allergy Clin Immunol Pract
. 2024 Dec;
13(2):353-360.
PMID: 39672377
Background: Patients with atopic dermatitis (AD) may discontinue dupilumab owing to dupilumab-induced ocular adverse events (DOAEs) or dupilumab-induced facial redness (DFR). Objective: To evaluate DOAE and DFR outcomes after switching...
4.
Fargeas M, Fauvernier M, Tauber M, Seneschal J, Verdu V, Bourrel Bouttaz M, et al.
Acta Derm Venereol
. 2024 Dec;
104:adv41184.
PMID: 39670437
In the era of biological treatments and small molecules, this study assessed therapeutic patient education (TPE) in managing adult atopic dermatitis (AD), focusing on disease severity, quality of life, and...
5.
Strizzolo R, Seneschal J, Soria A, Staumont-Salle D, Barbarot S, Viguier M, et al.
World Allergy Organ J
. 2024 Aug;
17(7):100923.
PMID: 39157196
In patients with moderate to severe atopic dermatitis (AD) showing an inadequate response to dupilumab 300mg/2weeks, few real-life studies reported the response to alternative regimen maintaining dupilumab. To assess and...
6.
Dupuis J, Tauber M, Mahe E, Jachiet M, Soria A, Tetart F, et al.
J Eur Acad Dermatol Venereol
. 2024 Jul;
39(2):e174-e178.
PMID: 39082796
No abstract available.
7.
Reynaud V, Chircop I, Hacard F, Nicolas J, Berard F, Mosnier A, et al.
Eur J Dermatol
. 2024 Jul;
34(3):341-342.
PMID: 39015989
No abstract available.
8.
A Lio P, Armstrong A, Gutermuth J, Nosbaum A, Sofen H, Garcia Gil E, et al.
Dermatol Ther (Heidelb)
. 2024 Jun;
14(7):1929-1943.
PMID: 38922484
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease for which signs and symptoms have a negative impact on a patient's quality of life (QoL) and mental health. Here,...
9.
Simpson E, Silverberg J, Nosbaum A, Winthrop K, Guttman-Yassky E, Hoffmeister K, et al.
Am J Clin Dermatol
. 2024 Jun;
25(4):639-654.
PMID: 38888681
Background: Abrocitinib, an oral, once-daily, Janus kinase 1-selective inhibitor, is efficacious in moderate-to-severe atopic dermatitis with a manageable long-term safety profile. Objective: We aimed to provide updated integrated long-term safety...
10.
Braun C, Badiou C, Guironnet-Paquet A, Iwata M, Lenief V, Mosnier A, et al.
J Allergy Clin Immunol
. 2024 May;
154(2):355-374.
PMID: 38734386
Background: The contribution of Staphylococcus aureus to the exacerbation of atopic dermatitis (AD) is widely documented, but its role as a primary trigger of AD skin symptoms remains poorly explored....